Librium and Nordiazepam
Also known as: LIB
Use
This test is used to optimize dosing and monitor patient adherence to Librium and Nordiazepam. Monitoring levels can help manage therapeutic drug dosing effectively and ensure that drug levels remain within a range that is both effective and non-toxic. Adverse effects related to these drugs can include drowsiness, ataxia, nausea, and constipation, underscoring the importance of monitoring.
Special Instructions
It is recommended to collect the patient specimen predose (trough) when the drug concentration is at a steady state. This ensures the most accurate assessment of the drug's therapeutic levels.
Limitations
This test cannot be used for initial diagnosis of drug overdose; it is intended for monitoring therapeutic levels. Variability in patient metabolism and other drugs can affect drug levels and interpretation. Hemolyzed samples, or those collected in inappropriate tubes such as gel separator tubes or sodium citrate, are not acceptable and will lead to test rejection.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 3457-9
- 3537-8
Result Turnaround Time
1-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
ARUP standard transport tube
Collection Instructions
Gray (potassium oxalate/sodium fluoride). Also acceptable are plain red, green (sodium heparin), lavender (K2 or K3EDTA), or pink (K2EDTA) tubes. Avoid gel separator tubes.
Patient Preparation
Collect predose (trough) at steady state concentration.
Storage Instructions
Refrigerated transport.
Causes for Rejection
Gel separator tubes, plasma or whole blood collected in sodium citrate, hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 2 weeks |
| Frozen | 3 years |